Insmed (NASDAQ:INSM) Earns “Equal Weight” Rating from Morgan Stanley

Insmed (NASDAQ:INSM)‘s stock had its “equal weight” rating reissued by analysts at Morgan Stanley in a research note issued on Wednesday, MarketBeat Ratings reports. They presently have a $126.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s price target suggests a potential downside of 1.37% from the stock’s current price.

A number of other analysts have also recently commented on the stock. Bank of America increased their price target on shares of Insmed from $94.00 to $109.00 and gave the company a “buy” rating in a research note on Wednesday, June 11th. Royal Bank Of Canada upped their target price on shares of Insmed from $108.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Wells Fargo & Company lifted their price target on Insmed from $130.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. boosted their price target on Insmed from $90.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 8th. Finally, The Goldman Sachs Group upped their price objective on Insmed from $100.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday, June 11th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $129.57.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $127.75 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock has a 50 day moving average price of $102.53 and a 200 day moving average price of $83.54. The stock has a market capitalization of $27.00 billion, a PE ratio of -22.37 and a beta of 0.95. Insmed has a 52 week low of $60.40 and a 52 week high of $128.48.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the company posted ($1.94) EPS. The company’s quarterly revenue was up 18.9% compared to the same quarter last year. Analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider directly owned 89,407 shares of the company’s stock, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 933 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $102.51, for a total value of $95,641.83. Following the transaction, the insider owned 66,394 shares in the company, valued at $6,806,048.94. The trade was a 1.39% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 525,716 shares of company stock valued at $49,665,671. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Insmed

A number of institutional investors have recently bought and sold shares of INSM. Cullen Frost Bankers Inc. increased its holdings in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP acquired a new stake in Insmed during the fourth quarter worth approximately $28,000. ORG Partners LLC grew its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares in the last quarter. Hilltop National Bank bought a new position in Insmed during the 2nd quarter worth $28,000. Finally, FNY Investment Advisers LLC acquired a new position in Insmed in the 2nd quarter valued at $33,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.